AMPRENAVIR

AMPRENAVIR 구조식 이미지
카스 번호:
161814-49-9
상품명:
AMPRENAVIR
동의어(영문):
VX 478;PROZEI;141W94;KVX-478;CS-1052;AGENERASE;AMPRENAVIR;Angenerase;Amprenavir 13C6;5-Bromo-5-nitro-1
CBNumber:
CB4186139
분자식:
C25H35N3O6S
포뮬러 무게:
505.63
MOL 파일:
161814-49-9.mol
MSDS 파일:
SDS

AMPRENAVIR 속성

녹는점
72-74°C
밀도
1.30±0.1 g/cm3(Predicted)
저장 조건
-20°C
용해도
DMSO: 용해성20mg/mL, 투명
물리적 상태
가루
산도 계수 (pKa)
11.54±0.46(Predicted)
색상
흰색에서 베이지색
optical activity
[α]/D +8 to +12°, c = 0.5 in methanol
BCS Class
2
InChIKey
YMARZQAQMVYCKC-OEMFJLHTSA-N
안전
  • 위험 및 안전 성명
  • 위험 및 사전주의 사항 (GHS)
유엔번호(UN No.) 3077
WGK 독일 3
HS 번호 29350090
유해 물질 데이터 161814-49-9(Hazardous Substances Data)
그림문자(GHS): GHS hazard pictograms
신호 어: Warning
유해·위험 문구:
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드
H302 삼키면 유해함 급성 독성 물질 - 경구 구분 4 경고 GHS hazard pictograms P264, P270, P301+P312, P330, P501
H315 피부에 자극을 일으킴 피부부식성 또는 자극성물질 구분 2 경고 GHS hazard pictograms P264, P280, P302+P352, P321,P332+P313, P362
H319 눈에 심한 자극을 일으킴 심한 눈 손상 또는 자극성 물질 구분 2A 경고 GHS hazard pictograms P264, P280, P305+P351+P338,P337+P313P
H332 흡입하면 유해함 급성 독성 물질 흡입 구분 4 경고 GHS hazard pictograms P261, P271, P304+P340, P312
H335 호흡 자극성을 일으킬 수 있음 특정 표적장기 독성 - 1회 노출;호흡기계 자극 구분 3 경고 GHS hazard pictograms
예방조치문구:
P261 분진·흄·가스·미스트·증기·...·스프레이의 흡입을 피하시오.
P280 보호장갑/보호의/보안경/안면보호구를 착용하시오.
P305+P351+P338 눈에 묻으면 몇 분간 물로 조심해서 씻으시오. 가능하면 콘택트렌즈를 제거하시오. 계속 씻으시오.

AMPRENAVIR C화학적 특성, 용도, 생산

개요

Amprenavir was launched as Agenerase in the US for the treatment of AIDS patients in combination with approved agent antiretroviral nucleoside analogs. It is the fifth non-peptidic inhibitor of HIV-1 protease to be marketed in this indication after the last approved Neflinavir. Amprenavir, designed via a structure-based process, is the smallest molecule in the 《navir》 class and exhibits a reduced peptidic character. An improved process for preparation comprising four steps from a (1S, 2R)-2-hydroxy-3-aminopropylcarbamate has been developed. Amprenavir is a potent inhibitor of HIV-1 aspartyl protease (Ki = 0.6nM), an enzyme required by the virus to cleave pro-form polyproteins to structural proteins during the last stage in the replication process. The compound displays good oral bioavailability in humans and penetrates the CNS, which is an important advantage in long-term treatment. Its plasma half-life is approximately 10h. Treatment with Amprenavir in combination with nucleoside analog reverse transcriptase inhibitors considerably decreases viral load and restores CD4+ T-cell counts in patients with HIV infection.

화학적 성질

Off-White to Pale Yellow

용도

A selective HIV protease inhibitor. An analogue of Ritonavir

Indications

Amprenavir (Agenerase) is administered twice daily, providing the patient with an advantage over other protease inhibitors that must be taken more frequently (e.g., indinavir, saquinavir). Common side effects of am-prenavir include nausea, vomiting, diarrhea, and perioral paraesthesias. Rash occurs in approximately 20 to 30% of patients and can be mild or severe (Stevens- Johnson syndrome).

원료

Mutations at position 50, 76 and 84 of the protease enzyme gene are associated with significantly reduced susceptibility.

일반 설명

Amprenavir is a second-generation drug derived from hydroxyethylamine sulfonamide.

Pharmaceutical Applications

A synthetic compound formulated as the calcium salt of the oral prodrug fosamprenavir.

Pharmacokinetics

Oral absorption: Not known/available
Cmax 700 mg + ritonavir 100 mg:c. 6.08 mg/L
twice daily
Cmin 700 mg + ritonavir 100 mg:c. 2.12 mg/L
twice daily
Plasma half-life: c. 7.7 h
Volume of distribution: c. 430 L
Plasma protein binding: c. 90%
Absorption
Fosamprenavir is rapidly and almost completely hydrolyzed to amprenavir and inorganic phosphate by cellular phosphatases in the gut epithelium as it is absorbed. Absolute bioavailability has not been established. It can be taken without regard to food.
Distribution
It penetrates moderately well into the CNS. The semen:plasma ratio is negligible. It is not known if it is distributed into breast milk.
Metabolism and excretion
It is extensively metabolized by the cytochrome P450 (CYP) 3A4 enzyme system. Two major metabolites have been identified that appear to result from the oxidation of the tetrahydrofuran and aniline moieties. Around 14% of a dose is eliminated in the urine and 75% in feces, <3% as unchanged drug. Metabolites account for >90% of administered drug found in fecal samples. It should be used with caution and at reduced doses in adults with mild or moderate hepatic impairment; it is contraindicated in patients with severe hepatic impairment.

Clinical Use

Treatment of HIV infection (in combination with other antiretroviral drugs)

부작용

The most common adverse events in patients receiving boosted fosamprenavir were diarrhea, nausea, headache, fatigue, vomiting and rash. Ritonavir-boosted fosamprenavir is associated with a dyslipidemia profile characteristic of those treated with other protease inhibitors boosted with 200 mg of ritonavir.

AMPRENAVIR 준비 용품 및 원자재

원자재

준비 용품


AMPRENAVIR 공급 업체

글로벌( 202)공급 업체
공급자 전화 이메일 국가 제품 수 이점
Alpha Biopharmaceuticals Co., Ltd
+86-411-39042497 +8613921981412
sales@alphabiopharm.com China 886 58
Capot Chemical Co.,Ltd.
571-85586718 +8613336195806
sales@capotchem.com China 29797 60
Hangzhou FandaChem Co.,Ltd.
008657128800458; +8615858145714
fandachem@gmail.com China 9338 55
Biochempartner
0086-13720134139
candy@biochempartner.com CHINA 967 58
Hubei Jusheng Technology Co.,Ltd.
18871490254
linda@hubeijusheng.com CHINA 28180 58
Alchem Pharmtech,Inc.
8485655694
sales@alchempharmtech.com United States 63711 58
HANGZHOU CLAP TECHNOLOGY CO.,LTD
86-571-88216897,88216896 13588875226
sales@hzclap.com CHINA 6313 58
Shaanxi Dideu Medichem Co. Ltd
+86-029-89586680 +86-18192503167
1026@dideu.com China 9126 58
AFINE CHEMICALS LIMITED
+86-0571-85134551
info@afinechem.com China 15396 58
Baoji Guokang Bio-Technology Co., Ltd.
0917-3909592 13892490616
gksales1@gk-bio.com China 9328 58

AMPRENAVIR 관련 검색:

Copyright 2019 © ChemicalBook. All rights reserved